WARRENDALE, Pa., June 12 /PRNewswire/ -- MEDRAD, INC., has signed a distribution and co-marketing partnership agreement with PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions USA, Inc. The agreement will enable health care providers to inject Fluorodeoxyglucose (FDG) for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures in an innovative, new way. The partnership will leverage MEDRAD's soon to be introduced PET infusion system and multi-dose FDG packaging and delivery from PETNET Solutions. PET/CT Imaging has proven effective in diagnosing and staging certain forms of cancer.
MEDRAD's PET infusion system, to be called Intego(TM), is designed to automatically extract a patient dose from a multi-dose vial and deliver it directly to the patient. The system is mobile and includes dosimetry, shielding, and a touchscreen interface -- all with precision, flexibility, and safety in mind.
PETNET Solutions has agreed to provide FDG to customers throughout its extensive, cyclotron-based radiopharmacy network in multi-dose vials and specially designed vial shields, which will allow for easy integration with MEDRAD's new system.
Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Medical Solutions USA, Inc., commented, "In addition to our traditional delivery method, by providing FDG in multi-dose vials compatible with the MEDRAD PET infusion system across our extensive network, we have the opportunity to help improve the way FDG is being handled and delivered."
Alan Connor, director of global marketing for MEDRAD Molecular Imaging,
said, "We are very pleased that PETNET Solutions is the first FDG provider
to agree to provide FDG in a manner compatible with the Intego System
across its entire network. From the beginning of t
|SOURCE MEDRAD, INC.|
Copyright©2008 PR Newswire.
All rights reserved